By Josh White
Date: Friday 21 Mar 2025
(Sharecast News) - Angle announced on Friday the successful completion of assay development projects for AstraZeneca and Eisai, further expanding its portfolio of liquid biopsy solutions and strengthening its position as a partner to the pharmaceutical industry in oncology drug development.
Angle's Parsortix system used in 'breakthrough' ... | 24-Jan-2025 | ShareCast |
Berenberg slashes target price on Angle | 23-Jan-2025 | ShareCast |
Angle signs new agreement US biotech Recursion | 19-Sep-2024 | ShareCast |
Angle unveils plans to raise more than £10m | 05-Jun-2024 | ShareCast |
Angle reports promising results from Parsortix s... | 16-May-2024 | ShareCast |
Notice of Results | 23-May-2025 | 07:00 | RNS |
Issue of LTIP Options and Share Options | 21-Mar-2025 | 07:00 | RNS |
Results of Eisai Phase 2 pilot study | 21-Mar-2025 | 07:00 | RNS |
Analysis of CTC-DNA and ctDNA using Illumina assay | 29-Jan-2025 | 07:00 | RNS |
Trading Update | 23-Jan-2025 | 07:00 | RNS |
Market report: Monday latest | 07-Apr-2008 | Daily Mail |
T&T float sinks amid turmoil | 07-Feb-2008 | Times |
Carphone buzz may just be empty static | 01-Feb-2008 | Guardian |
Greene King looks to life after cigarette ban | 02-Jul-2007 | The Independent |
The Week Ahead: BSkyB boosted by 200,000 new sub... | 29-Jan-2007 | The Independent |
No recent information was found.
Currency | UK Pounds |
Share Price | 10.50p |
Change Today | 0.50p |
% Change | 5.00 % |
52 Week High | 19.47 |
52 Week Low | 7.25 |
Volume | 3,598,449 |
Shares Issued | 322.64m |
Market Cap | £33.88m |
RiskGrade | 312 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 1 |
Buy | 0 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
17:07 | 114,988 @ 10.50p |
16:28 | 51,843 @ 10.34p |
16:24 | 5,000 @ 10.36p |
12:38 | 8,000 @ 10.79p |
12:37 | 12,000 @ 10.79p |
CEO | Andrew D Newland |
Finance Director | Ian F Griffiths |
Chair | Jan Groen |
You are here: research